Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0 Increased by +100% | - |
| Mar 27, 24 | 0 Increased by +100% | -0.18 Increased by +100% |
| Nov 9, 23 | -0.31 Decreased by -3.33% | -0.19 Decreased by -63.16% |
| Aug 10, 23 | -0.34 Decreased by -6.25% | -0.3 Decreased by -13.33% |
| May 11, 23 | -0.3 Increased by +6.25% | -0.35 Increased by +14.29% |
| Mar 30, 23 | -0.18 Decreased by -158.06% | -0.31 Increased by +41.94% |
| Nov 10, 22 | -0.3 Decreased by -15.38% | -0.35 Increased by +14.29% |
| Aug 5, 22 | -0.32 Decreased by -3.23% | -0.41 Increased by +21.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by -100% | -8.44 M Increased by +0.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by -100% | -9.61 M Decreased by -2.21 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by -100% | -7.86 M Decreased by -208.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 31 K Increased by 0% | 10.65 M Increased by +567.42% | Increased by +34.36 K% Increased by +567.42% |
| Sep 30, 22 | 31 K Increased by 0% | -8.49 M Increased by +47.44% | Decreased by -27.4 K% Increased by +47.44% |
| Jun 30, 22 | 31 K Increased by 0% | 455 K Increased by +102.66% | Increased by +1.47 K% Increased by +102.66% |
| Mar 31, 22 | 31 K Increased by 0% | 7.24 M Increased by +261.63% | Increased by +23.35 K% Increased by +261.63% |
| Dec 31, 21 | 31 K Increased by 0% | 1.6 M Increased by +115.23% | Increased by +5.15 K% Increased by +115.23% |